- £174.00m
- £167.99m
- £38.44m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 60.83 | ||
| PEG Ratio (f) | 0.72 | ||
| EPS Growth (f) | 531.53% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.49 | ||
| Price to Tang. Book | 7.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.21 | ||
| EV to EBITDA | 29.57 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.94% | ||
| Return on Equity | -0.71% | ||
| Operating Margin | -1.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 46.72 | 56.35 | 24.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -10.93 | +27.42 | n/a | n/a | n/a | +430.7 | +534.88 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Diaceutics PLC is a United Kingdom-based company. The Company is engaged in research and development activities in the area of precision medicine data and platform software. It provides pharma and biotech companies with an end-to-end commercialization solution for precision medicine through data analytics, scientific and advisory services enabled by its platform DXRX - The Diagnostics Network. It has two separate products and service lines: Insight & Engagement Solutions (Data and related information services) and Scientific & Advisory Services (Professional services). Insight & Engagement Solutions includes access to the DXRX platform diagnostic testing data repository to utilize licensed data insight products, such as lab segmentation, physician segmentation, testing rate tracker and physician signal. Scientific Advisory Services comprise a range of services developed to help improve patient care by accelerating the development, delivery and uptake of precision medicine.
Directors
- Peter Keeling NEC
- Ryan Keeling CEO
- Nick Roberts CFO
- Graham Paterson NID (55)
- Madeline Brown VPR
- Gosia Leitch VPR
- Scott Phillips VPR
- Cheryl Macdiarmid NED (57)
- Sandra Blake CHO
- Kerri Donaldson VPR
- Amie Mcneice VPR
- Marianna Sciortino VPR
- Lauren Dewitt EVP
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- May 17th, 2005
- Public Since
- March 21st, 2019
- No. of Employees
- 205
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
London Stock Exchange- Shares in Issue
- 85,291,958
- Address
- First Floor, BELFAST, BT9 6GW
- Web
- https://www.diaceutics.com/
- Phone
- Auditors
- Ernst & Young
Latest News for DXRX
Upcoming Events for DXRX
Similar to DXRX
Amcomri
London Stock Exchange
Andrews Sykes
London Stock Exchange
Ashtead Technology Holdings
London Stock Exchange
Boku
London Stock Exchange
BTG Consulting
London Stock Exchange
FAQ
As of Today at 01:16 UTC, shares in Diaceutics are trading at 204.00p. This share price information is delayed by 15 minutes.
Shares in Diaceutics last closed at 204.00p and the price had moved by +25.54% over the past 365 days. In terms of relative price strength the Diaceutics share price has outperformed the FTSE All Share Index by +13.13% over the past year.
The overall consensus recommendation for Diaceutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDiaceutics does not currently pay a dividend.
Diaceutics does not currently pay a dividend.
Diaceutics does not currently pay a dividend.
To buy shares in Diaceutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 204.00p, shares in Diaceutics had a market capitalisation of £174.00m.
Here are the trading details for Diaceutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: DXRX
Based on an overall assessment of its quality, value and momentum Diaceutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Diaceutics is 213.00p. That is 4.41% above the last closing price of 204.00p.
Analysts covering Diaceutics currently have a consensus Earnings Per Share (EPS) forecast of £0.01 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diaceutics. Over the past six months, its share price has outperformed the FTSE All Share Index by +9.72%.
As of the last closing price of 204.00p, shares in Diaceutics were trading +27.35% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Diaceutics PE ratio based on its reported earnings over the past 12 months is 60.83. The shares last closed at 204.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Diaceutics' management team is headed by:
- Peter Keeling - NEC
- Ryan Keeling - CEO
- Nick Roberts - CFO
- Graham Paterson - NID
- Madeline Brown - VPR
- Gosia Leitch - VPR
- Scott Phillips - VPR
- Cheryl Macdiarmid - NED
- Sandra Blake - CHO
- Kerri Donaldson - VPR
- Amie Mcneice - VPR
- Marianna Sciortino - VPR
- Lauren Dewitt - EVP